首页> 外国专利> 1-(6-(3-HYDROXYNAPHTHALEN-1-YL)QUINAZOLIN-2-YL)AZETIDIN-1-YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER

1-(6-(3-HYDROXYNAPHTHALEN-1-YL)QUINAZOLIN-2-YL)AZETIDIN-1-YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER

机译:1-(6-(3-(羟基)吡啶并萘-1-基)喹唑啉-2-基)氮杂环丁烷-1-基)丙-2-烯-1-酮衍生物和类似化合物作为KRAS G12C抑制剂治疗癌症

摘要

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (Formula (I)) or a pharmaceutically acceptable salt, stereoisomer thereof, wherein G, Y, R, R1, R2a, R2b, R2c, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. Preferred compounds are quinazoline and quinazolinone derivatives and in particular 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds.
机译:提供了具有作为G12C突变体KRAS蛋白的抑制剂的活性的化合物。化合物具有以下结构(I):(式(I))或其药学上可接受的盐,立体异构体,其中G,Y,R,R 1,R 2a,R 2b,R 2c,L,L 1和E如本文所定义。还提供了与此类化合物的制备和使用相关的方法,包含此类化合物的药物组合物以及调节G12C突变体KRAS蛋白活性以治疗疾病例如癌症的方法。优选的化合物是喹唑啉和喹唑啉酮衍生物,特别是1-(6-(3-羟基萘-1-基)喹唑啉-2-基)氮杂环丁烷-1-基)丙-2-烯-1-酮衍生物和类似化合物。

著录项

  • 公开/公告号EP3573970A1

    专利类型

  • 公开/公告日2019-12-04

    原文格式PDF

  • 申请/专利权人 ARAXES PHARMA LLC;

    申请/专利号EP20180703448

  • 申请日2018-01-24

  • 分类号C07D403/14;C07D403/12;A61K31/517;A61P35;

  • 国家 EP

  • 入库时间 2022-08-21 11:37:56

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号